February 14, 2008 - The New Mexico Institute of Mining and Technology (New Mexico Tech) and Biomoda Inc. have partnered with the New Mexico Department of Veterans Services (DVS) to conduct a $350,000 clinical study using proprietary testing technology for detection of early lung cancer in the state’s veterans.

The clinical program will be administered by New Mexico Tech, a science and engineering research university in Socorro. Biomoda, through its Albuquerque office, will conduct the first year of the program using its patented noninvasive diagnostic technology for screening of early stage lung cancer in large populations. New Mexico Tech and the New Mexico Department of Veterans Services will oversee the clinical program.

Biomoda's technology is based on an application that identifies cancerous or aberrant cells from samples of lung sputum. Cancerous cells glow red under fluorescent light and can be detected under a microscope. The technology is noninvasive and designed for cancer screening of large populations at a reasonable cost.

Biomoda’s team of experts will be dedicated to the year long clinical study. The team includes representatives from TriCore Laboratories, Averion International, and Quintiles Consulting. The Black Veterans Association of New Mexico will assist with outreach to veterans.

For more information: www.biomoda.com


Related Content

News | Artificial Intelligence

September 7, 2023 — Paige, a provider of end-to-end digital pathology solutions and clinical AI, has announced a ...

Time September 07, 2023
arrow
News | Radiology Business

July 27, 2023 — Privately-held biotech company TAE Life Sciences has announced that its board of directors has appointed ...

Time July 27, 2023
arrow
News | Interventional Radiology

Varian announced it has signed an asset purchase agreement to acquire the Boston Scientific portfolio of drug-loadable microsphere and bland embolic bead products for treating arteriovenous malformations and hypervascular tumors. When completed, this acquisition, in combination with the recent acquisitions of Endocare and Alicon, will expand Varian's portfolio of multidisciplinary integrated cancer care solutions.

Time July 03, 2019
arrow
Technology | Focused Ultrasound Therapy

Insightec announced that the U.S. Food and Drug Administration (FDA) has approved an expansion of the indication of Exablate Neuro to include the treatment of patients with tremor-dominant Parkinson's disease (PD).

Time December 21, 2018
arrow
Videos | Radiation Oncology

Genomics can be used to assess a patient's radiosensitivity, which can be used to increase or decrease the radiation ...

Time November 06, 2018
arrow
News | Radiation Dose Management

AngioDynamics Inc. announced an agreement to acquire RadiaDyne, a privately held medical diagnostic and device company that designs and develops patient dose monitoring technology to improve cancer treatment outcomes.

Time September 24, 2018
arrow
News | Radiation Oncology

World Cancer Day takes place annually on Feb. 4 to raise awareness and education in the media, governments and people ...

Time February 01, 2018
arrow
News | Oncology Related Products

December 19, 2016 — Children’s National Health System and Celsion Corp. announced in November the launch of a clinical ...

Time December 19, 2016
arrow
News | Clinical Decision Support

October 27, 2016 — The National Comprehensive Cancer Network (NCCN) continues to build its library of appropriate use ...

Time October 27, 2016
arrow
News | Ultrasound Imaging

September 12, 2016 — Tiny microbubbles are being used to more effectively identify liver tumors, according to a study ...

Time September 12, 2016
arrow
Subscribe Now